# Remimazolam Bolus for General Anesthesia

> **NCT04901871** · PHASE3 · COMPLETED · sponsor: **Gangnam Severance Hospital** · enrollment: 120 (actual)

## Conditions studied

- Loss of Consciousness

## Interventions

- **DRUG:** 0.02 mg/kg, age<65
- **DRUG:** 0.07 mg/kg, age<65
- **DRUG:** 0.12 mg/kg, age<65
- **DRUG:** 0.17 mg/kg, age<65
- **DRUG:** 0.22 mg/kg, age<65
- **DRUG:** 0.27 mg/kg, age<65
- **DRUG:** 0.02 mg/kg, age≥65
- **DRUG:** 0.07 mg/kg, age≥65
- **DRUG:** 0.12 mg/kg, age≥65
- **DRUG:** 0.17 mg/kg, age≥65
- **DRUG:** 0.22 mg/kg, age≥65
- **DRUG:** 0.27 mg/kg, age≥65

## Key facts

- **NCT ID:** NCT04901871
- **Lead sponsor:** Gangnam Severance Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-27
- **Primary completion:** 2021-07-20
- **Final completion:** 2021-07-26
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2021-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04901871

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04901871, "Remimazolam Bolus for General Anesthesia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04901871. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*